Ovid Therapeutics Inc (OVID)

OVID...................................p/m

OVID.....................................https://stockcharts.com/sc3/ui/?s=OVID&p=w&b=5&g=0&id=p86431144783

Ovid Therapeutics secures $60M funding to advance epilepsy drug programsMarch 18, 2026 10:58 AM
IH Market News
Ovid Therapeutics Inc. (NASDAQ:OVID) said Wednesday it has raised $60 million through a private placement to support the continued development of its epilepsy drug candidate OV329, including expanding research into seizures linked to tuberous sclerosis complex and infantile spasms. The biotechnology company, currently valued at about $262 million, has seen its shares climb roughly 337% over the past year and was recently trading around $2.01.The company also released new data from the 7 mg dose cohort of OV329, a GABA-aminotransferase inhibitor. According to Ovid, no treatment-related adverse events were observed. Across both single and multiple ascending dose groups, the study recorded 19 unrelated adverse events, all described as mild and temporary.Ovid plans to begin a Phase 2 randomized, placebo-controlled trial in the second quarter of 2026 to test two dose levels of OV329 in patients with treatment-resistant focal onset seizures. Additional studies are planned, including a proof-of-concept trial targeting seizures associated with tuberous sclerosis complex expected to begin in the fourth quarter of 2026, and a separate study for infantile spasms scheduled for 2027.Meanwhile, the company’s OV4071 program—an oral KCC2 direct activator—has received approval from a Human Research Ethics Committee and acknowledgment from Australia’s Therapeutic Goods Administration. This clearance activates a 30-day window for holders of the company’s Series A Warrants to exercise their options, which expire on April 17, 2026. If all warrants are exercised, Ovid could receive up to $53.9 million in additional gross proceeds.As of December 31, 2025, Ovid reported $90.4 million in cash, cash equivalents and marketable securities, which it believes will be sufficient to fund operations into late 2028. If the outstanding warrants are fully exercised, the company said its financial runway could extend into 2029.The private placement includes the issuance of 19,154,321 common shares priced at $2.01 each, along with pre-funded warrants allowing investors to purchase up to 10,701,710 additional shares at $2.009 per warrant.For the fourth quarter ended December 31, 2025, Ovid reported net income of $9.7 million, compared with a net loss of $9.3 million in the same period a year earlier. The quarterly profit was largely driven by a $21 million gain tied to a revaluation of a long-term equity investment. Despite the positive quarter, the company remains unprofitable over the past 12 months, reporting a loss per share of $0.50, and analysts do not expect profitability this year.In other developments, Ovid recently announced the $60 million private investment in public equity (PIPE) financing led by Point72, with participation from existing investors including Adage Capital Management and RA Capital Management. The company intends to use the funds to accelerate its pipeline development.Ovid also reported encouraging results from a Phase 1 trial of OV350, described as the first KCC2 direct activator tested in humans. The study met its primary safety and pharmacokinetic goals and reported no serious treatment-related adverse events. Conducted with 16 healthy volunteers, the trial demonstrated a favorable safety profile, marking another step forward in the company’s clinical development efforts.Ovid Therapeutics stock price

Original: Ovid Therapeutics secures $60M funding to advance epilepsy drug programs

OVID..................................p/m

OVID..............................https://stockcharts.com/sc3/ui/?s=OVID&p=W&b=5&g=0&id=p86431144783

OVID..........................................https://stockcharts.com/sc3/ui/?s=OVID&p=D&yr=0&mn=3&dy=0&id=p11960084343

Ovid reports positive Phase I data for epilepsy therapy OV329

Oct 6, 2025

Ovid Therapeutics has released positive topline data from its Phase I trial involving healthy volunteers, evaluating OV329, a next-generation gamma-aminobutyric acid (GABA)-aminotransferase (GABA-AT) inhibitor under development for drug-resistant epilepsy.

The trial focused on assessing the pharmacodynamics, pharmacokinetics, tolerability and safety of the therapy, revealing inhibitory activity and a potential safety profile.

Ovid Therapeutics chairman and CEO Dr Jeremy Levin said: “OV329 was designed to deliver the benefits of a novel GABA-AT inhibitor while avoiding the challenges of existing medicines.

“Our Phase I trial generated the first-in-human data, supported by what we believe is the most extensive biomarker programme in early seizure drug development, showing consistent results across multiple validated measures and demonstrating a clean ocular and overall safety profile.”

The study assessed OV329 in 68 healthy participants, comprising 51 individuals receiving the active treatment and 17 receiving a placebo, across both multiple and single ascending dose cohorts.

Doses ranging from 1mg to 5mg were tested as part of the trial, safety assessments of which included ophthalmic evaluations.

Comprehensive exploratory biomarker analyses were performed in the 3mg and 5mg multiple ascending dose cohorts.

These analyses utilised transcranial magnetic stimulation, as measured by electromyography, to implement established metrics for assessing anti-seizure medications, including long-interval intracortical inhibition and the cortical silent period.

Furthermore, electroencephalography and magnetic resonance spectroscopy were examined to investigate markers of target engagement and inhibitory activity.

OV329 showed a favourable tolerability and safety profile in the trial and all potentially adverse events related to the treatment were observed to be mild and transient.

Additionally, Ovid is planning to launch a Phase IIa randomised placebo-controlled trial of OV329.

This trial, set to be initiated in the second quarter of 2026, will evaluate the therapy in adults with drug-resistant focal onset seizures, with completion anticipated in mid-2027.

Link article

$OVID

OVID............................https://stockcharts.com/h-sc/ui?s=OVID&p=W&b=5&g=0&id=p86431144783

$2+ 😃

==================

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Oct 3, 2025

Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of up to $175 million to the Company, including initial gross proceeds of approximately $81 million, in each case before placement agent fees and offering expenses. The PIPE financing is expected to close on or about October 6, 2025, subject to satisfaction of customary closing conditions.

The PIPE financing included participation from new investors Janus Henderson Investors, RA Capital Management, Eventide Asset Management, Coastlands Capital, Blue Owl Healthcare Opportunities, Balyasny Asset Management, Saturn V Capital and Ally Bridge Group, alongside existing investors including ADAR1 Capital Management and Affinity Healthcare Fund, LP, as well as new and existing large investment management firms.

Pursuant to the terms of the securities purchase agreement, the Company is selling an aggregate of (i) 57,722 shares of its Series B non-voting convertible preferred stock (the “Series B Preferred Stock”), (ii) Series A warrants (the “Series A Warrants”) to purchase 38,481,325 shares of its common stock and/or pre-funded warrants (the “Pre-Funded Warrants”) and (iii) Series B warrants to purchase 28,861,000 shares of its common stock and/or Pre-Funded Warrants (the “Series B Warrants”). Each share of Series B Preferred Stock is being sold together with a Series A Warrant to purchase 666.66 shares of common stock and/or Pre-Funded Warrants (rounded down to next whole share based on each investor’s aggregate purchase) and a Series B Warrant to purchase 500 shares of common stock and/or Pre-Funded Warrants, referred to collectively as a “Security.” The Security will be sold at a purchase price of $1,400.00 per Security. The Series A Warrants and Series B Warrants will each have an exercise price of $1.40 per share.

The shares of Series B Preferred Stock are convertible into an aggregate of 57,722,000 shares of the Company’s common stock, with each share of Series B Preferred Stock being convertible into 1,000 shares of common stock, subject to the approval of the Company’s stockholders and certain beneficial ownership limitations set by each holder.

The Series A Warrants will be exercisable following receipt of approval by the Company’s stockholders and will terminate upon the earlier of (a) the 30th calendar day following the date on which the Company publicly announces the clearance of the first of any investigational new drug application, clinical trial application or other foreign equivalent with respect to the clinical development of the Company’s OV4071 product candidate and (b) October 6, 2030. The Series B Warrants will be exercisable following receipt of Ovid stockholder approval and will terminate on October 6, 2030, subject to the mandatory exercise requirement, which requires the holder to exercise of Series A Warrants upon achievement of certain stock trading prices of the Company’s common stock. Subject to the satisfaction of the applicable conditions precedent and assuming the exercise of all the Series A Warrants and Series B Warrants for cash, the Company will receive aggregate gross proceeds of $94.3 million. Assuming the satisfaction of the applicable conditions precedent, the conversion of all shares of Series B Preferred Stock and the exercise of all of the Series A Warrants and Series B Warrants for cash, the Company will issue an aggregate of 125,064,325 shares of its common stock in connection with the PIPE financing.

The Company intends to use the net proceeds from the initial closing of the PIPE financing, together with the Company’s existing cash, cash equivalents and marketable securities, to provide financing for research and development, general corporate expenses, and working capital needs. The Company expects that its cash will fund its operating plan into 2028.

TD Cowen, Leerink Partners and Oppenheimer & Co. are acting as joint placement agents for the PIPE financing.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Concurrently with the execution of the securities purchase agreement, Ovid and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issuable upon conversion of the Series B Preferred Stock and the shares of common stock issuable upon exercise of each of the Series A Warrants, the Series B Warrants and/or Pre-Funded Warrants, in each case sold in the PIPE financing.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders.

https://investorshub.advfn.com/stock-market/NASDAQ/ovid-therapeutics-OVID/stock-news/96944695/ovid-therapeutics-announces-pricing-of-private-pla

=================

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Oct 3, 3025

Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced positive topline results from its Phase 1 healthy volunteer study evaluating the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) activity of OV329, a next generation GABA-aminotransferase (GABA-AT) inhibitor being developed for drug-resistant epilepsies.

“OV329 was designed to deliver the benefits of a novel GABA-AT inhibitor while avoiding the challenges of existing medicines. Our Phase 1 trial generated the first-in-human data, supported by what we believe is the most extensive biomarker program in early seizure drug development, showing consistent results across multiple validated measures and demonstrating a clean ocular and overall safety profile,” said Dr. Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer of Ovid Therapeutics. “We believe these results reinforce OV329’s therapeutic potential, and we are excited to advance it further in development alongside our rapidly progressing KCC2 direct activator portfolio, as we continue our commitment to developing innovative therapies for patients that address diseases and symptoms caused by excessive neural excitation.”

“The results from this study provide unequivocal evidence that support the advancement of OV329 into further studies in patients with epilepsy,” said Alexander Rotenberg, MD, PhD, Director of Neuromodulation at Boston Children’s Hospital, professor of neurology at Harvard Medical School, and world-leading expert in the application of TMS biomarkers for the study of ASMs. “These early data confirm that OV329 is getting into the brain and exerting concentration-dependent inhibition, as shown by the highly significant correlation between OV329 blood exposure and long-interval intracortical inhibition (LICI).”

TRIAL DESIGN
The Phase 1 trial evaluated OV329 in 68 healthy volunteers, including 51 participants taking active treatment and 17 participants receiving placebo, across single and multiple ascending dose cohorts. Doses tested ranged from 1 mg – 5 mg. The study assessed safety, tolerability, pharmaco-kinetic and pharmacodynamic activity, with safety evaluations including rigorous ophthalmic evaluations. Extensive exploratory biomarker analyses were conducted in the 3 mg (active n=6; pbo n=2) and 5 mg (active n=15; pbo n=5) MAD cohorts. These analyses leveraged transcranial magnetic stimulation (TMS) as measured with electromyography (EMG) to apply established measures for evaluating anti-seizure medicine such as LICI and the cortical silent period (CSP), which have been previously used to assess the inhibition of therapeutic doses of vigabatrin (VGB).1,2,3 All TMS biomarkers were studied across two muscle groups; including the first dorsal interosseous (FDI), a muscle in the hand located between the thumb and index finger and the abductor pollicis brevis (APB), a thumb muscle at the base of the palm.

Additionally, magnetic resonance spectroscopy (MRS) and electroencephalography (EEG) were studied to explore markers of target engagement and inhibitory activity, respectively. MRS measured GABA levels in the medial parietal lobe and EEG assessed brainwave activity.

Active participants received OV329 via a once-daily oral capsule at 3 mg or 5 mg doses. All biomarker results compared participant findings from their pre-treated baseline on Day 1 to their post-treatment findings on Day 7 and relative to placebo. Where methods were reproduceable, OV329 outcomes were compared to previously published studies of VGB as measured in healthy volunteers at confirmed therapeutic doses.

https://investorshub.advfn.com/stock-market/NASDAQ/ovid-therapeutics-OVID/stock-news/96944602/ovid-announces-positive-topline-results-for-the-ne

$OVID

$1.64+ 😃

$OVID

OV329's Phase 1 trial is projected to produce positive topline safety, tolerability, and biomarker results in Q3 2025, supporting advancement to later-stage trials. Its potent preclinical profile, favorable safety in early cohorts, and novel biomarker strategy indicate a high likelihood of success in this Phase 1 study.

OVID.....................................https://stockcharts.com/h-sc/ui?s=OVID&p=W&b=5&g=0&id=p86431144783

$OVID 💹 😃

$1.22 😃

======================

Lucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 Target

August 23, 2025

Link article

$OVID 💹

HOD $0.86 😃

$OVID 💹

OVID..................................................................https://stockcharts.com/h-sc/ui?s=OVID&p=W&b=5&g=0&id=p86431144783

Based on 5 Wall Street analysts who have issued ratings for Ovid Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 4 have given a buy rating, and 1 has given a strong buy rating for OVID.

According to the 5 analysts' twelve-month price targets for Ovid Therapeutics, the average price target is $3.13. The highest price target for OVID is $4.00, while the lowest price target for OVID is $1.50. The average price target represents a forecasted upside of 412.30% from the current price of $0.61.

https://www.marketbeat.com/stocks/NASDAQ/OVID/forecast/

======================

Price Target
Based on short-term price targets offered by four analysts, the average price target for Ovid Therapeutics comes to $2.88. The forecasts range from a low of $1.50 to a high of $4.00. The average price target represents an increase of 423.64% from the last closing price of $0.55.

Broker Rating
Ovid Therapeutics currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.

Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.

https://www.zacks.com/stock/research/OVID/price-target-stock-forecast

======================

(Price targets are not always met. But a nice increase is certainly possible here)

$OVID

Chart looks ready. Watching 🤓

$OVID 💹

$OVID 💹

OVID under $2

OVID................................https://stockcharts.com/h-sc/ui?s=OVID&p=W&b=5&g=0&id=p86431144783

OVID under $2

OVID 3.48 - setup for a freeroll???

$3 netcash-per-share?

Takeda, going forward, to incur all research expenses?

Two Phase-3-commencement announcement catalysts upcoming in 2021?

Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021. If successful, Takeda estimates that soticlestat could receive approval in its fiscal year 2023.

https://docoh.com/filing/1636651/0001564590-21-044455/OVID-8K/file/2

Oh, the boredom that 6 buy ratings gets you. Poor OVID board.

Slow climb to earnings in a couple weeks.

Held up well during a blood couple of days. Earnings coming up in two weeks.

Up a bit PM... not bad at all after the jump.

Someone just bought 200k share block not long ago we know it’s worth more way more

Holding very well on an ugly day- love it!

15 in 3 months I’ll wait with 300m plus cash and milestones kicking in

Should be a good month for OVID. ;)

* * $OVID Video Chart 03-03-2021 * *

Link to Video - click here to watch the technical chart video

Curling back up..let’s best that intraday high of 4.75 going into power hour!

Looks like a 20 dollar stock soon manipulation at its finest shakeout on bs trades for the big dogs lol this stock worth 8 minimum with that news today now I’m holding for a month to 20 obvious big boys want in cheap

$OVID is screaming for the top after the company announced that Takeda has purchased the rights to a key candidate. https://cnafinance.com/ovid-stock-ovid-therapeutics-climbs-on-takeda-agreement/

$OVID

Nice, $3s very possible today .

BCLI, I made out so far on selling $5 puts for the 18th, have had those awhile and will probably buy them back this week if the stock drops a little. OVID on the other hand my 12/11 $5 puts were already assigned. Not looking good for those, I need a $4 share price by next Friday to break even. BCLI has been a much better play.

The company still at strong buy, by 7 analysts .

I’ve seen some play like this and they had good news after the bad news and it went back up right away, I’m not saying it will happen here, but I think people over react to the news today, should bounce some tomorrow imo, market cap over $420M !!

That’s good enough for me .

Just like BCLI. you will get a 20% jump between now and friday. This always happens, the selling is always overdone on these biotechs

way oversold. They are not a one trick pony

$OVID I’m in should have a nice bounce of this level .

big dip in ah's

3.28 in ah's

This could turn out to be
the best buying day we've
seen a quite a while.

I managed to get 500 shares
at $6.50. Just missed getting
500 at $6.40. Oh well.

I'll try to buy
before 2PM today.

What can we expect from the
presentation tomorrow?

new article out today at PSN:

https://pennystocks.news/why-ovid-therapeutics-is-on-the-radar-of-many-farmaceutical-investors-ovid/